prikaz prve stranice dokumenta Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
  Download
PDF 425.35 KB
Scientific paper - Original scientific paper
Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
Journal of Neuroimmunology, 362 (2022); 577788. https://doi.org/10.1016/j.jneuroim.2021.577788
Adamec, Ivan; Rogić, Dunja; Penz, Monika-Gabriele; Braun, Carola; Habek, Mario

Linked objects
COVID-19 | Virtual collection

Institutional repository: Dr Med - University of Zagreb School of Medicine Digital Repository

Cite this document

Adamec, I., Rogić, D., Penz, M. G., Braun, C. & Habek, M. (2022). Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. Journal of Neuroimmunology, 362.. doi: 10.1016/j.jneuroim.2021.577788

Adamec, Ivan, et al. "Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab." Journal of Neuroimmunology, vol. 362, 2022. https://doi.org/10.1016/j.jneuroim.2021.577788

Adamec, Ivan, Dunja Rogić, Monika Gabriele Penz, Carola Braun and Mario Habek. "Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab." Journal of Neuroimmunology 362 (2022). https://doi.org/10.1016/j.jneuroim.2021.577788

Adamec, I., et al. (2022) 'Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab', Journal of Neuroimmunology, 362. doi: 10.1016/j.jneuroim.2021.577788

Adamec I, Rogić D, Penz MG, Braun C, Habek M. Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab. Journal of Neuroimmunology [Internet]. 2022 January 15 [cited 2024 November 05];362. doi: 10.1016/j.jneuroim.2021.577788

I. Adamec, D. Rogić, M. G. Penz, C. Braun and M. Habek, "Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab", Journal of Neuroimmunology, vol. 362, January 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:570068. [Accessed: 05 November 2024]

Metadata
Title (english)Humoral and cellular immunity in convalescent COVID-19 people with multiple sclerosis treated with ofatumumab
AuthorIvan Adamec
AuthorDunja Rogić
MBZ: 147641
AuthorMonika-Gabriele Penz
AuthorCarola Braun
AuthorMario Habek
Author's institutionUniversity of Zagreb
School of Medicine
(Department of Neurology)
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Neurology
Abstract (english)
Objectives: To report clinical outcome, development of humoral and T-cell mediated immunity in convalescent COVID-19 people with multiple sclerosis (pwMS) treated with ofatumumab in the ALITHIOS study from a single center. ----- Methods: Testing for SARS-Cov2 IgG antibodies was performed on two occasions with at least three months apart between the two testing. During the second antibody testing, interferon-γ ELISpot was used to assess cellular immunity. ----- Results: All four subjects had mild COVID-19 infection without any sequelae. In all subjects except subject 2, COVID-19 was confirmed with PCR. Subjects 1, 2 and 4 had normal levels of IgM and IgG without measurable counts of CD19 cells prior to COVID-19. Subject 3 administered the last dose of ofatumumab 24 days prior to COVID-19 symptoms, but had a gap of 28 weeks of ofatumumab application beforehand due to low IgM levels. Subject 4 received COVID-19 vaccinations before second testing, so second testing and T-cell immunity testing were not performed. Subjects who were CD19 depleted did not had measurable levels of SARS-Cov2 IgG antibodies. Subject 3 had first and second SARS-COV2 titer of 118 U/ml and > 250 U/ml, respectively. All three pwMS showed T cell immunity against SARS-CoV-2. Quotient of basal spots divided by interferon-γ secreting spot forming units were 4, 8 and 14.7 SI in subjects 1, 2 and 3, respectively (>3 considered reactive).
Keywords (english)
Languageenglish
Publication typeScientific paper - Original scientific paper
Publication statusPublished
Peer reviewPeer review
Publication versionPublished version
Journal titleJournal of Neuroimmunology
Numberingvol. 362, 577788
p-ISSN0165-5728
e-ISSN1872-8421
DOIhttps://doi.org/10.1016/j.jneuroim.2021.577788
URN:NBNurn:nbn:hr:105:570068
Publication2022-01-15
Document URLhttps://linkinghub.elsevier.com/retrieve/pii/S0165572821003155
Type of resourceText
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2022-02-03 08:22:46